Abstract 153P
Background
Gastric cancer (GC) is an aggressive cancer and it is thought that they have a worse prognosis in AYA due to delayed diagnosis and a more aggressive tumour biology. There is an increasing trend to adopt next-generation sequence (NGS) to identify tumour genomic alterations for precision medicine in AYA. We aim to study the differences in the mutational landscape of GC in AYA and how it correlates to outcomes in a single-centre high-volume Asian institution.
Methods
Patients diagnosed between 16-39 years old with GC between 2015 to 2019 in our centre, National Cancer Centre Singapore, were included in this study.
Results
A total of 50 AYA GC patients were referred to NCCS between 1st January 2015 and 31st December 2019. 7 patients were excluded from this analysis (3 due to incomplete data and 4 were neuroendocrine tumours). The median age (n=43) was 35(22-39) with 22 males (51.2%) and majority (53.5%, n=23) having signet ring cell carcinoma. 28 patients (65.1%) had metastatic disease at diagnosis. Out of the 43 patients, only 60.5%(n=26) and 58.1%(n=25) were tested for programmed death-ligand 1(PD-L1) and DNA mismatch repair (MMR) respectively. 1 patient (3.8%) had MLH 1 loss and 1 patient (4.5%) had PD-L1 percentage of more than 50% by using combined positive score (CPS). 32 patients (74.4%) had the human epidermal growth factor receptor 2(HER2) tested, of which 5 were HER2 positive (15.6%). With a median follow-up of 11 months, median OS was 16.0 months (range 0.5- 111.3 months). There was no significant differences between subgroups with regards to age(p=0.931), presence of signet-ring histology (p=0.135), histology grade (p=0.384) and HER2 positivity (p=0.66).
Conclusions
Gastric cancer in the young behaves differently and generally seem more aggressive in the young regardless of gender. Further studies to evaluate how the differences in the mutational landscape of gastric cancer in the adolescents and young adults impact prognosis and treatment paradigm.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
276P - Sarcopenia to predict overall survival in head and neck cancer patients receiving chemotherapy: A systematic review and meta-analysis
Presenter: Felix Kwenandar
Session: e-Poster Display Session
277P - Tegafur/uracil, platinum and cetuximab (UPEx) as first line treatment in frail patients with recurrent or metastatic head and neck squamous cell carcinoma
Presenter: Meng-che Hsieh
Session: e-Poster Display Session
278P - Serial assessment of parotid volume changes during radical chemoradiation of locally advanced head and neck cancer: Its implications in practice of adaptive radiotherapy
Presenter: Aathira T S
Session: e-Poster Display Session
279P - Clinico pathological characteristics and survival outcome in oral cavity cancer with masticator space involvement (T4b): A retrospective single institutional experience
Presenter: Abdulla Kunnummal Palathinkara
Session: e-Poster Display Session
280P - Safety and efficacy of concurrent chemoradiotherapy for head and neck cancers in younger versus older patients: Post hoc analysis of a randomized control trial
Presenter: Vanita Noronha
Session: e-Poster Display Session
281P - Prevalence of premalignant lesions and oral cancer among tobacco-using tea plantation workers of Nilgiri Hills, Tamilnadu, India
Presenter: Delfin Lovelina Francis
Session: e-Poster Display Session
282P - Filipino head and neck cancer patients and their quality of life
Presenter: Frederic Ivan Ting
Session: e-Poster Display Session
283P - Descriptive epidemiology of head and neck cancer in Niger: First results from the National Cancer Registry
Presenter: Salamatou Mamoudou Garba
Session: e-Poster Display Session
284P - Outcomes of metronomic adjuvant chemotherapy with tegafur-uracil in locally advanced head and neck squamous cell carcinoma
Presenter: Tsung-jang Yeh
Session: e-Poster Display Session
285P - Comparison of induction chemotherapy plus concurrent chemoradiotherapy and concurrent chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma: A meta-analysis
Presenter: Xu Guoqiang
Session: e-Poster Display Session